Terray Therapeutics

We are excited to announce our multi-target research collaboration with Gilead Sciences to discover and develop novel small molecule therapies! Our tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. This iterative approach applies AI-empowered methods to an extensive library of quantitative, purpose-built, structure activity data to find the right molecules to solve complex problems in drug discovery. We are very proud to strategically partner with Gilead and look forward to leveraging our unique blend of experimentation and computation alongside the deep expertise of our collaborators at Gilead to find transformational small molecule therapeutics that bring relief to patients in need. Learn More: https://lnkd.in/gmZ8A3Kx #drugdiscovery #biotech #generativeAI #ML

Thank you to Brittany Trang and STAT for featuring Terray Therapeutics! Our platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges for patients with high unmet medical need. Read the Article: https://lnkd.in/gNSMZJb4 #generativeAI #ML #drugdiscovery #biotech

Thank you BioSpace for recognizing Terray Therapeutics as one of the Best Places to Work in Life Sciences 2025! We are honored to be recognized for the third year in a row and deeply proud of our culture and brilliant team. We are hiring — come join us on our journey to advance human health by transforming the speed, cost, and success rate of small molecule drug discovery using computation integrated with novel data at scale.   Join Us: https://lnkd.in/gQEC55Jn Learn More: https://lnkd.in/eVW6vt-2   #generativeAI #ML #drugdiscovery #biotech

Interested to learn more about how we built the world's largest experimental chemistry dataset (growing by 500M+ measurements a month), and transformed the way experimentation and computation work together to solve the toughest therapeutic challenges? Join our Chief Platform Officer Craig Schulz at the Future Labs, Automation & Technology conference in San Diego on November 12th!

It's been an amazing month at Terray! We had a great time with Nasdaq celebrating our $120M Series B financing, led by Bedford Ridge Capital and NVentures, NVIDIA’s venture capital arm! And we announced our strategic collaboration with Odyssey Therapeutics to jointly discover and develop first-in-class transcription factor therapies! Our platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges for patients with high unmet medical need. Learn more about our Series B: Press Release: https://lnkd.in/gcRiJUKd Endpoints News Exclusive: https://lnkd.in/gtieiu2P Learn More about our strategic collaboration with Odyssey Therapeutics: https://lnkd.in/gkaVaEUJ #generativeAI #ML #drugdiscovery #biotech

We are excited to announce our strategic collaboration with Odyssey Therapeutics to jointly discover and develop first-in-class transcription factor therapies!   At Terray, our proprietary ultra-miniaturized chemistry platform enables unique generative AI capabilities for the discovery and development of small molecule therapeutics. This approach is a perfect complement for Odyssey’s transcription factor biology expertise. We believe that our discovery capabilities and combined expertise in immunology affords us the opportunity to solve incredibly hard challenges and bring relief to patients.   Learn More: https://lnkd.in/gqd4rB62 #generativeAI #ML #drugdiscovery #biotech

I’m excited to be participating in GEN's conference: The State of AI in Drug Discovery. I'm on a panel discussion alongside other leaders in the field discussing “Key considerations for Small Molecule Drug Discovery” on Wednesday October 30th at 11AM! Join 3,000 other participants and register for free: https://lnkd.in/gfARfDBq

Thank you Nasdaq for celebrating our $120M Series B financing, led by Bedford Ridge Capital and NVentures, NVIDIA’s venture capital arm! Our platform uniquely blends experimentation and computation to identify and optimize novel small molecule solutions to the most complex problems. This financing will allow us to advance our internal programs to the clinic to bring medicines to patients in need. Press Release: https://lnkd.in/gcRiJUKd Endpoints Exclusive: https://lnkd.in/gtieiu2P #generativeAI #ML #drugdiscovery #biotech

We’re thrilled to announce our $120M Series B funding round led by Bedford Ridge Capital and NVentures, NVIDIA’s venture capital arm. Our platform uniquely blends experimentation and computation to identify and optimize novel small molecule solutions to the most complex problems. This financing will allow us to advance our internal programs to the clinic to bring medicines to patients in need. Press Release: https://lnkd.in/gcRiJUKd Endpoints Exclusive: https://lnkd.in/gtieiu2P #generativeAI, #ML, #drugdiscovery, #biotech

Terray Therapeutics, backed by NVentures, has launched a cutting-edge #generativeAI model called COATI-LDM. This model uses multidisciplinary latent diffusion techniques to design small molecules with specific properties. COATI-LDM represents a significant step forward in inverse design for #drugdiscovery and #pharma applications. Terray Therapeutics exemplifies how NVIDIA DGX Cloud can impact #lifesciences applications. Their COATI-LDM model was trained exclusively on a distributed cluster of A100 GPUs in the NVIDIA DGX Cloud, showcasing the platform's powerful capabilities. The COATI-LDM model offers several key features: ✅Control over multiple properties ✅Generation guided by medicinal chemistry preferences ✅Ability to create similar compounds while optimizing specific molecular properties Read the arXiv preprint to learn more https://nvda.ws/3MgI6GG